News BioNTech SE

Equities

BNTX

US09075V1026

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
86.71 ^USD	-1.57%		+0.63%	-17.84%

Apr. 25	Sector Update: Health Care Stocks Drop in Afternoon Trading	MT
Apr. 25	GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Drop in Afternoon Trading	Apr. 25	MT
GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines	Apr. 25	MT
GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines	Apr. 25	MT
GSK Files Lawsuit Against Pfizer, BioNTech Over mRNA Patents Infringement	Apr. 25	MT
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology	Apr. 25	RE
Scholz promises support for pharma sector in Germany as Merck invests	Apr. 25	RE
Big pharma giants in English High Court for global Covid dispute	Apr. 24	AQ
BIONTECH : Gets a Neutral rating from Deutsche Bank	Apr. 23	ZD
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024	Apr. 22	GL
Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla...	Apr. 15
Market outlook is uncertain, but optimism prevails	Apr. 15
BioNTech : Invitation to the Annual General Meeting 2024 - Form 6-K	Apr. 08	PU
BioNTech SE Announces Three-Year Follow-Up Data from Phase 1 Trial with the mRNA-Based Individualized Neoantigen-Specific Immunotherapy Candidate Autogene Cevumeran	Apr. 08	CI
BioNTech Reports Positive 3-Year Data From Phase 1 Trial of Cevumeran in Pancreatic Cancer	Apr. 08	MT
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer	Apr. 07	AQ
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer	Apr. 07	GL
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher	Apr. 01	MT
UBS Cuts BioNTech Price Target to $101 From $110, Maintains Neutral Rating	Mar. 27	MT
WuXi Biologics Reports Solid 2023 Annual Results	Mar. 27	AQ
News Highlights : Top Company News of the Day - Tuesday at 7 AM ET	Mar. 26	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

BIONTECH : A miss is a miss

March 21, 2024 at 09:27 am EDT